Stock ALIF B ADDLIFE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials AddLife AB

Equities

ALIF B

SE0014401378

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:54 2024-04-26 am EDT 		5-day change 1st Jan Change
98.65 SEK +2.02% Intraday chart for AddLife AB +0.46% -9.83%
Apr. 24 Transcript : AddLife AB, Q1 2024 Earnings Call, Apr 24, 2024
Apr. 24 AddLife AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 46,512 13,229 13,331 12,022 - -
Enterprise Value (EV) 1 50,269 13,229 18,523 16,860 15,876 15,653
P/E ratio 63.5 x 27.5 x 70.1 x 45.4 x 28.1 x 21 x
Yield 0.52% - 0.46% 0.88% 1.35% 1.91%
Capitalization / Revenue 5.82 x 1.46 x 1.38 x 1.17 x 1.11 x 1.01 x
EV / Revenue 6.29 x 1.46 x 1.91 x 1.64 x 1.46 x 1.31 x
EV / EBITDA 34.1 x 8.65 x 12.3 x 11.3 x 9.85 x 8.6 x
EV / FCF 57.4 x - 40.6 x 22.8 x 19.6 x 17 x
FCF Yield 1.74% - 2.46% 4.38% 5.1% 5.88%
Price to Book 10.8 x - 2.69 x 2.33 x 2.18 x 2.03 x
Nbr of stocks (in thousands) 121,952 121,812 121,857 121,864 - -
Reference price 2 381.4 108.6 109.4 98.65 98.65 98.65
Announcement Date 2/4/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 7,993 9,084 9,685 10,295 10,842 11,945
EBITDA 1 1,474 1,530 1,504 1,498 1,612 1,820
EBIT 1 996 808 585 710 806.4 1,003
Operating Margin 12.46% 8.89% 6.04% 6.9% 7.44% 8.4%
Earnings before Tax (EBT) 1 927 602 339 405.7 578.5 754.4
Net income 1 719 480 190 264.8 428.6 573.4
Net margin 9% 5.28% 1.96% 2.57% 3.95% 4.8%
EPS 2 6.010 3.950 1.560 2.173 3.516 4.705
Free Cash Flow 1 876 - 456 738 809 921
FCF margin 10.96% - 4.71% 7.17% 7.46% 7.71%
FCF Conversion (EBITDA) 59.43% - 30.32% 49.28% 50.2% 50.59%
FCF Conversion (Net income) 121.84% - 240% 278.73% 188.76% 160.63%
Dividend per Share 2 2.000 - 0.5000 0.8691 1.328 1.882
Announcement Date 2/4/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,131 2,579 2,457 2,365 2,319 2,544 2,570 2,552 2,445 2,728
EBITDA 1 388 509 448 342 332 - 384 371 333 409
EBIT 1 245 338 258 136 132 - 186 176 147 201
Operating Margin 11.5% 13.11% 10.5% 5.75% 5.69% - 7.24% 6.9% 6.01% 7.37%
Earnings before Tax (EBT) 1 - 289 206 70 61 2 100 102 74 130
Net income 1 178 225 174 33 26 -41 62 67 49 86
Net margin 8.35% 8.72% 7.08% 1.4% 1.12% -1.61% 2.41% 2.63% 2% 3.15%
EPS 2 1.450 - 1.430 0.2700 0.2000 -0.3400 0.5200 0.5500 0.4000 0.7100
Dividend per Share - - - - - - - - - -
Announcement Date 2/4/22 4/28/22 4/26/23 7/14/23 10/26/23 2/2/24 4/24/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 3,757 - 5,192 4,838 3,855 3,631
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.549 x - 3.452 x 3.23 x 2.392 x 1.995 x
Free Cash Flow 1 876 - 456 738 809 921
ROE (net income / shareholders' equity) 22% - 4% 5.23% 8.03% 10%
ROA (Net income/ Total Assets) - - 1.47% 2.08% 3.65% 4.41%
Assets 1 - - 12,901 12,748 11,739 13,007
Book Value Per Share 2 35.20 - 40.70 42.40 45.20 48.50
Cash Flow per Share 8.460 - - - - -
Capex 1 134 - 286 252 226 269
Capex / Sales 1.68% - 2.95% 2.45% 2.08% 2.25%
Announcement Date 2/4/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AddLife AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
98.65 SEK
Average target price
137 SEK
Spread / Average Target
+38.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ADDLIFE AB Stock AddLife AB
-9.83% 1.1B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALIF B Stock
  4. Financials AddLife AB